Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
$0.70
-4.2%
$0.78
$0.38
$115.57
$7.91M0.711.65 million shs65,504 shs
Dyadic International Inc. stock logo
DYAI
Dyadic International
$0.80
+1.5%
$0.96
$0.71
$2.20
$29.02M0.8978,544 shs189,901 shs
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$3.87
-0.3%
$4.33
$3.62
$9.18
$28.33M0.6538,837 shs10,172 shs
MAAQ
Mana Capital Acquisition
$3.67
-1.3%
$3.96
$5.35
$10.25
$29.82MN/A33,075 shs17,671 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
-3.56%+6.07%-6.52%+50.41%-98.98%
Dyadic International Inc. stock logo
DYAI
Dyadic International
-0.62%-7.04%-18.85%-23.28%-41.90%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
+0.52%-0.51%-10.80%-3.24%-36.57%
MAAQ
Mana Capital Acquisition
+2.48%+7.83%-13.49%-21.85%+779.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
3.4141 of 5 stars
3.55.00.00.00.61.71.9
Dyadic International Inc. stock logo
DYAI
Dyadic International
3.3549 of 5 stars
3.55.00.00.02.43.30.0
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
3.6686 of 5 stars
3.20.00.04.61.92.50.6
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
3.00
Buy$360.0051,328.57% Upside
Dyadic International Inc. stock logo
DYAI
Dyadic International
3.00
Buy$6.00648.13% Upside
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
2.33
Hold$9.00132.56% Upside
MAAQ
Mana Capital Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest AEON, KZR, DYAI, and MAAQ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/AN/AN/AN/A($4.12) per shareN/A
Dyadic International Inc. stock logo
DYAI
Dyadic International
$3.49M8.32N/AN/A($0.01) per share-80.20
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
$7M4.05N/AN/A$12.53 per share0.31
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
-$36.63M-$6.083.89N/AN/AN/AN/A-994.63%N/A
Dyadic International Inc. stock logo
DYAI
Dyadic International
-$5.81M-$0.19N/AN/AN/A-134.84%-355.39%-60.66%N/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$83.74M-$9.69N/AN/AN/AN/A-63.51%-52.13%N/A
MAAQ
Mana Capital Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A

Latest AEON, KZR, DYAI, and MAAQ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Dyadic International Inc. stock logo
DYAI
Dyadic International
-$0.06-$0.06N/A-$0.06$0.60 million$0.97 million
8/13/2025Q2 2025
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
-$2.15-$1.87+$0.28-$1.87N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/AN/AN/AN/AN/A
Dyadic International Inc. stock logo
DYAI
Dyadic International
N/AN/AN/AN/AN/A
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
N/AN/AN/AN/AN/A
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
N/A
0.22
0.22
Dyadic International Inc. stock logo
DYAI
Dyadic International
5.40
2.02
2.02
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
0.03
7.29
7.29
MAAQ
Mana Capital Acquisition
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
22.78%
Dyadic International Inc. stock logo
DYAI
Dyadic International
27.95%
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
67.90%
MAAQ
Mana Capital Acquisition
68.44%
CompanyEmployeesShares OutstandingFree FloatOptionable
AEON Biopharma, Inc. stock logo
AEON
AEON Biopharma
511.31 million74.37 millionNot Optionable
Dyadic International Inc. stock logo
DYAI
Dyadic International
736.19 million25.51 millionOptionable
Kezar Life Sciences, Inc. stock logo
KZR
Kezar Life Sciences
607.32 million6.64 millionNot Optionable
MAAQ
Mana Capital Acquisition
18.13 millionN/ANot Optionable

Recent News About These Companies

Decentraland (CRYPTO: MANA)

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON Biopharma stock logo

AEON Biopharma NASDAQ:AEON

$0.70 -0.03 (-4.24%)
Closing price 03:48 PM Eastern
Extended Trading
$0.69 -0.01 (-0.86%)
As of 04:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Dyadic International stock logo

Dyadic International NASDAQ:DYAI

$0.80 +0.00 (+0.61%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Kezar Life Sciences stock logo

Kezar Life Sciences NASDAQ:KZR

$3.89 +0.01 (+0.36%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Mana Capital Acquisition NASDAQ:MAAQ

$3.67 -0.05 (-1.34%)
As of 08/19/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.